JPMorgan Has Consistently Beaten Its Own 17% Return Target Under Jamie Dimon. Is the Stock Still a Buy?

JPMorgan Chase reported Q2 revenue of $58B, up 27% YoY, and EPS of $7.70, up 47% YoY, with all business units posting record revenue. ROTCE (excluding special items) came in at 23%—above its 17% long-term target—while management flagged potential growth slowdown ahead (possibly around 2027–2028) and cautioned against buying the broader market at high valuation. The article frames JPM as a favorable long-term buy given the favorable rate/M&A backdrop and a “fortress” balance sheet, with the stock trading at a 15x P/E.

Analysis

The setup still favors the highest-quality money center balance sheet, but the market should be careful extrapolating peak-cycle profitability. JPM’s earnings power is being driven by a rare overlap of stable funding, active capital markets, and a benign rate backdrop; that mix tends to compress quickly when one leg rolls over, so the next 1-3 quarters matter more than the reported 23% return metric. If activity stays firm, JPM should keep taking share from BAC and WFC because its cost of capital is effectively lower, letting it reinvest harder in technology, underwriting, and trading capacity without sacrificing returns.

The second-order loser is less “the banks” than banks with weaker operating leverage and stickier expense bases. BAC and WFC need either stronger loan growth or materially better deposit pricing to keep up; otherwise, JPM’s outperformance can force them into defensive pricing and higher compensation spend, which delays operating leverage recovery. NDAQ is a quieter beneficiary if the active-deals backdrop persists, since equity issuance and market volatility lift ancillary fee pools, but that support is much more sensitive to a slowdown in risk appetite.

Contrarian view: consensus is treating this as a durable quality premium, but the more important question is whether this is a cyclical peak in fee income and net interest margin. If the Fed cuts faster, NII can roll over before expense discipline is fully absorbed; if growth slows, credit costs re-enter the debate and the multiple should stop expanding. The thesis is falsified if next-quarter net interest income or investment banking fees flatten materially, or if management lowers 2026–2027 growth assumptions.

Key Decisions for Investors

• Long JPM / short BAC for the next 1-3 months as a relative-quality pair: JPM should keep earning a premium ROE multiple while BAC has more room for margin disappointment if rates back off. Falsify if BAC shows a clear deposit beta reset or sharper expense leverage than expected.
• Add to JPM on pullbacks rather than chasing here; preferred expression is 3-6 month call spreads to limit valuation risk while keeping upside if earnings revisions stay positive. Risk/reward is better than outright stock if the tape already prices in near-peak results.
• Watch WFC as a laggard in the same factor basket: if the market starts rewarding bank quality over beta, WFC likely underperforms JPM first. Use any strength in WFC relative to JPM as a short-entry signal.
• If M&A and ECM volumes remain elevated into the next quarter, consider a small tactical long in NDAQ as a second-order beneficiary of the same activity cycle. Exit if market issuance cools or VIX normalizes sharply.
• Set an alert for any guide-down in JPM NII or fee income; that would be the cleanest trigger to take profits on the long-bank-quality trade and rotate out of the sector.